Tumor suppressor reprogramming by EBV through post-translational modification
EBV 通过翻译后修饰重编程肿瘤抑制因子
基本信息
- 批准号:10684650
- 负责人:
- 金额:$ 53.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2027-08-31
- 项目状态:未结题
- 来源:
- 关键词:AIDS-Related LymphomaAcetylationAcetyltransferaseAcquired Immunodeficiency SyndromeAffectAutomobile DrivingB Cell ProliferationB lymphocyte immortalizationB-Cell LymphomasB-LymphocytesBindingBiochemicalBurkitt LymphomaCell CycleCell Cycle ProgressionCell Cycle Progression PathwayCell Cycle RegulationCell SurvivalCell modelCellsComplexCyclin D1CyclinsDNA DamageDegradation PathwayDiseaseE2F transcription factorsEpstein Barr Virus B cell lymphomaEpstein-Barr Virus InfectionsEpstein-Barr Virus latencyEscherichia coliFamilyFamily memberGene ExpressionGenesGenetic TranscriptionGenomeGoalsHIVHIV SeropositivityHodgkin DiseaseHumanHuman Herpesvirus 4Human Herpesvirus 8Human PapillomavirusImmuneImmunocompromised HostIn VitroIndividualInfectionInterventionKnock-outKnowledgeLeadLinkLymphomaMalignant - descriptorMalignant NeoplasmsMammalian CellMediatingModelingModificationMolecularMolecular BiologyMolecular GeneticsMutateNon-Hodgkin&aposs LymphomaNuclear AntigensNuclear ProteinOncogenesOncogenicOncogenic VirusesPathologyPatientsPhenotypePhosphorylationPhosphotransferasesPolyomavirusPost-Translational Protein ProcessingProliferatingProteinsRecombinantsRegulationRetinoblastoma ProteinRoleSatellite VirusesSiteTestingTherapeutic InterventionTranscription RepressorTumor Suppressor ProteinsUbiquitinationUntranslated RNAViralViral GenesViral GenomeVirus DiseasesWestern Blottingcell transformationco-infectiongammaherpesvirusinfected B cellinsightlymphoblastoid cell linemolecular modelingmulticatalytic endopeptidase complexmutantnew therapeutic targetnovelnovel therapeutic interventionpost-transplantprogramsrecombinant virusrecruitresponsetargeted treatmenttranscription factortransforming virus
项目摘要
Abstract:
Immunocompromised HIV-positive patients have serious complications with opportunistic
oncogenic viral infections that can lead B-cell lymphomas. Epstein-Barr virus (EBV) and
Kaposi’s sarcoma associated virus (KSHV) are two human oncogenic gammaherpesviruses
associated with B-cell lymphomas either individually or as co-infections. EBV-associated B-cell
lymphomas are established as latency III infection with the major latent genes expressed as well
as the small non-coding RNAs. EBV transformed B cells drive latency III, also seen in HIV
associated EBV-positive lymphomas. EBV is also associated with other lymphomas including
Burkitt’s lymphoma, Hodgkin’s and non-Hodgkin’s lymphoma, and post-transplant and AIDS
associated lymphomas in immunocompromised HIV-patients. EBV also efficiently transforms
human primary B-cells in vitro, into immortalized lymphoblastoid cell lines (LCLs). These
nascent transformed B cells express latent genes, one of which is the Epstein-Barr nuclear
antigen EBNA3C, essential for immortalization of B-cells. EBNA3C regulates cellular and viral
gene expression through interaction with transcription repressors, and complexes of the
mammalian cell cycle which include CyclinA, and components of the SCF proteosome
degradation pathway. Our long term goal is to determine the role of EBNA3C in reprogramming
viral and infected cell genomes through interactions with the tumor suppressor Rb and the
regulatory consequences of these interactions as related to cell survival, cell cycle regulation
and proliferation. We will investigate the mechanism of Rb regulation through specific post-
translation modifications after infection by EBV, which includes phosphorylation and acetylation
important for targeted ubiquitination. We will determine if enhanced phosphorylation/acetylation
of Rb occurs through recruitment of CyclinD/Cdk4/6 complexes by EBNA3C important for cell
cycle progression. This results in loss of Rb through ubiquitination which leads to cell and viral
genome reprogramming by activation of the cellular E2F pathway, cell cycle progression,
increased survival and malignant transformation. These studies will examine the role of
EBNA3C in regulating the Rb/CyclinD/E2F network important for B-cell immortalization with
implications for novel insights into KSHV and EBV contributions to latency III lymphomas in HIV
patients.
抽象的:
免疫功能低下的艾滋病毒阳性患者会出现严重的机会性并发症
致癌病毒感染可导致 B 细胞淋巴瘤 (EBV) 和
卡波西肉瘤相关病毒 (KSHV) 是两种人类致癌性伽马疱疹病毒
单独或与 EBV 相关 B 细胞感染相关。
淋巴瘤被确定为潜伏 III 感染,主要潜伏基因也表达
EBV 转化的 B 细胞驱动潜伏期 III,这也见于 HIV 中。
相关 EBV 阳性淋巴瘤也与其他淋巴瘤相关。
伯基特淋巴瘤、霍奇金淋巴瘤和非霍奇金淋巴瘤以及移植后和艾滋病
免疫功能低下的 HIV 患者的相关淋巴瘤也能有效转化。
人类原代 B 细胞在体外转化为永生化类淋巴母细胞系 (LCL)。
新生转化的 B 细胞表达潜在基因,其中之一是 Epstein-Barr 核
抗原 EBNA3C,对于 B 细胞永生化至关重要 EBNA3C 调节细胞和病毒。
通过与转录抑制子和复合物的相互作用来表达基因
哺乳动物细胞周期,包括 CyclinA 和 SCF 蛋白酶体成分
我们的长期目标是确定 EBNA3C 在重编程中的作用。
通过与肿瘤抑制因子 Rb 和
这些相互作用的调节后果与细胞存活、细胞周期调节有关
我们将通过特定的后处理研究Rb的调节机制。
EBV 感染后的翻译修饰,包括磷酸化和乙酰化
对于靶向泛素化很重要,我们将确定磷酸化/乙酰化是否增强。
Rb 的发生是通过 EBNA3C 募集 CyclinD/Cdk4/6 复合物而发生的,这对细胞很重要
这导致 Rb 通过泛素化而丢失,从而导致细胞和病毒。
通过激活细胞 E2F 通路、细胞周期进程进行基因组重编程,
这些研究将探讨增加生存率和恶性转化的作用。
EBNA3C 调节 Rb/CyclinD/E2F 网络,对 B 细胞永生化很重要
对 KSHV 和 EBV 对 HIV 潜伏性 III 淋巴瘤的影响的新见解的意义
患者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ERLE S. ROBERTSON其他文献
ERLE S. ROBERTSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ERLE S. ROBERTSON', 18)}}的其他基金
Botswana-UPenn: Research Consortium of HPV-Related Cervical Cancer in HIV Patient
博茨瓦纳-宾夕法尼亚大学:HIV 患者 HPV 相关宫颈癌研究联盟
- 批准号:
10834480 - 财政年份:2023
- 资助金额:
$ 53.33万 - 项目类别:
Project 2: KSHV induces tumorigenesis by harnessing differentiation in hypoxia
项目2:KSHV利用缺氧条件下的分化诱导肿瘤发生
- 批准号:
10714174 - 财政年份:2023
- 资助金额:
$ 53.33万 - 项目类别:
Project 1: KSHV reprograms replication and metabolic activities in hypoxia
项目 1:KSHV 在缺氧条件下重新编程复制和代谢活动
- 批准号:
10714173 - 财政年份:2023
- 资助金额:
$ 53.33万 - 项目类别:
Transcription and Replication of Oncogenic Viruses in Hypoxia
缺氧条件下致癌病毒的转录和复制
- 批准号:
10714172 - 财政年份:2023
- 资助金额:
$ 53.33万 - 项目类别:
Tumor suppressor reprogramming by EBV through post-translational modification
EBV 通过翻译后修饰重编程肿瘤抑制因子
- 批准号:
10402055 - 财政年份:2022
- 资助金额:
$ 53.33万 - 项目类别:
Epigenetic Regulation of KSHV Genome Replication
KSHV 基因组复制的表观遗传调控
- 批准号:
10208828 - 财政年份:2019
- 资助金额:
$ 53.33万 - 项目类别:
Epigenetic Regulation of KSHV Genome Replication
KSHV 基因组复制的表观遗传调控
- 批准号:
10669729 - 财政年份:2019
- 资助金额:
$ 53.33万 - 项目类别:
相似国自然基金
SCML4协同乙酰化转移酶HBO1促进Trm表观遗传修饰增强抗肿瘤免疫的分子机制研究
- 批准号:82303153
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
核苷酸转移酶cGAS乙酰化修饰抑制剂的设计、合成及抗自身免疫性疾病的机制研究
- 批准号:82273767
- 批准年份:2022
- 资助金额:51 万元
- 项目类别:面上项目
组蛋白乙酰化转移酶KAT7在血管衰老中的作用及表观遗传机制研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
ac4C乙酰化转移酶NAT10通过促进HMGB1转录介导CD8+T细胞节律紊乱与功能抑制的机制研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
N端乙酰转移酶蛋白家族在核糖体上乙酰化修饰的分子机理研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
The role N-terminal acetylation in dilated cardiomyopathy and associated arrhythmia
N-末端乙酰化在扩张型心肌病和相关心律失常中的作用
- 批准号:
10733915 - 财政年份:2023
- 资助金额:
$ 53.33万 - 项目类别:
Dissecting out differential molecular phenotypes across Lysine(K) AcetylTransferase mutations in mouse development
剖析小鼠发育过程中赖氨酸(K)乙酰转移酶突变的差异分子表型
- 批准号:
10727966 - 财政年份:2023
- 资助金额:
$ 53.33万 - 项目类别:
Synthetic Lethal Targeting of CREBBP/EP300 in Head and Neck Squamous Cell Carcinoma
CREBBP/EP300 在头颈鳞状细胞癌中的合成致死靶向
- 批准号:
10804966 - 财政年份:2023
- 资助金额:
$ 53.33万 - 项目类别:
The Role of Microbiome Composition in Amphetamine Abuse
微生物组组成在安非他明滥用中的作用
- 批准号:
10656799 - 财政年份:2023
- 资助金额:
$ 53.33万 - 项目类别: